Daily Brief Thematic (Sector/Industry): [IO Technical 2025/19]: Bearish Signals Persist Despite Brief Rally and more

In today’s briefing:

[IO Technical 2025/19]: Bearish Signals Persist Despite Brief Rally
#144 India Insight: IndusInd Execs in Insider Trade Row, Dabur Eyes M&A, Paytm’s Founder Banned
APAC Healthcare Weekly (May 11)- Shionogi, Daiichi Sankyo, HK Inno, Neuren, Biocon, Aster DM, Lupin

[IO Technical 2025/19]: Bearish Signals Persist Despite Brief Rally

SGX Iron Ore Futures rose $2.45/ton WoW to $98.30/ton, supported by stimulus hopes and US-China trade talks, before facing resistance near the upper Bollinger Band.
Prices remain below major moving averages despite a bullish MACD crossover, with a recent death cross and RSI at 46.83 indicating mixed momentum and limited upside.
Managed Money increased net short positions, while Physicals turned net long; total futures and options open interest dropped 11.14% WoW, signaling reduced overall market participation.

Grant Thornton’s forensic review finds IndusInd Bank executives traded shares before public disclosure of accounting lapses, raising insider trading concerns.
Dabur India Ltd (DABUR IN) plans to streamline its portfolio, focus on e-commerce and quick-commerce, and explore M&A in health and wellness.
Vijay Shekhar Sharma, Paytm (PAYTM IN) founder, banned for three years from receiving Esops; settles Sebi case with penalties.

Shionogi is acquiring Torii Pharmaceutical and pharmaceutical business of Japan Tobacco. Daiichi Sankyo’s Enhertu meets main goal in the neoadjuvant setting (before surgery) in early-stage breast cancer trial.
HK inno.N received approval for the domestic phase 3 clinical trial of obesity drug candidate. Neuren Pharmaceuticals’ Daybue recorded $84.6M revenue in the U.S. in 1Q25, up 11% YoY.
Biocon secured multiple market access agreements for Yesintek, its biosimilar to Stelara. Lupin received FDA approval for antiretroviral agent raltegravir tablets for the treatment of human immunodeficiency virus (HIV-1) infection.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network